Skip to main content

Table 1 Clinical data and main genetic findings of 34 unfavorable neuroblastomas

From: Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation

ID

Age

Sex

Stage

Outcome

Followup

Survival median

Site

WCA

WCA

SCA

SCA

MNA

11q-

Array platform

 

(mo)

 

(INRGSS)

 

(mo)

(mo)

 

(nr)

(average)

(nr)

(average)

   

52*

4

m

M

DOD

10

 

adr

0

 

6

 

+

 

32K

55

8

f

M

DOD

16

 

adr

0

 

6

 

+

 

32K, Affymetrix

106*

10

f

M

NED

265

 

adr

0

 

12

 

+

 

32K

123*

11

f

M

DOD

3

 

adr

0

 

6

 

+

 

32K, Affymetrix

241*

11

m

M

DOD

8

 

adr

1

 

3

 

+

 

32K, Affymetrix

244

14

f

M

DOD

22

 

adr

8

 

2

 

+

 

Affymetrix

212

15

m

M

DOD

5

 

adr

0

 

2

 

+

 

32K, Affymetrix

240*

21

f

M

NED

43

 

adr

0

 

3

 

+

 

32K, Affymetrix

135*

22

m

L2

DOD

3

 

adr

0

 

3

 

+

 

32K, Affymetrix

95*

26

f

M

DOD

15

 

adr

0

 

8

 

+

 

32K

238

30

f

M

DOD

24

 

adr

0

 

6

 

+

 

Affymetrix

207

37

f

M

DOD

7

 

adr

2

 

5

 

+

 

32K, Affymetrix

217

37

m

M

DOD

36

 

adr

0

 

8

 

+

 

32K

126

138

m

M

DOD

9

 

adr

0

 

7

 

+

 

32K, Affymetrix

MNA not11q-

     

9.5

  

0.8

 

5.5

   

68

41

m

M

DOD

12

 

adr

9

 

7

 

+

+

32K, Affymetrix

136*

48

f

L2

DOD

12

 

adr

1

 

8

 

+

+

32K

MNA & 11q-

     

12.0

  

5.0

 

7.5

   

243

32

f

M

DOD

28

 

adr

2

 

10

  

+

Affymetrix

149

34

m

M

DOD

16

 

adr

0

 

12

  

+

32K, Affymetrix

112

40

m

M

DOD

18

 

adr

1

 

3

  

+

32K, Affymetrix

111*

42

f

M

NED

262

 

adr

0

 

7

  

+

32K

155

52

f

M

DOD

19

 

adr

3

 

13

  

+

32K, Affymetrix

32*

57

m

M

DOD

12

 

adr

2

 

15

  

+

32K, Affymetrix

110

60

m

M

DOD

12

 

adr

1

 

14

  

+

32K, Affymetrix

69*

60

m

L2

DOD

17

 

th

1

 

14

  

+

32K, Affymetrix

41*

77

f

M

DOD

8

 

th

2

 

15

  

+

32K, Affymetrix

49

82

m

M

DOD

14

 

adr

3

 

10

  

+

32K, Affymetrix

209

129

m

M

DOD

35

 

adr

2

 

10

  

+

32K, Affymetrix

229

169

m

L2

DOD

34

 

adr

1

 

21

  

+

32K, Affymetrix

11q- notMNA

     

16.5

  

1.5

 

12.0

   

107*

23

m

M

DOD

10

 

adr

1

 

2

   

32K, Affymetriix

131

37

f

L2

DOD

21

 

adr

13

 

1

   

32K, Affymetriix

130

46

m

M

DOD

57

 

adr

0

 

3

   

32K, Affymetriix

208

59

m

L2

DOD

25

 

renal

4

 

3

   

32K

242*

90

f

M

SD

37

 

th

12

 

5

   

32K, Affymetriix

226*

91

m

M

SD

61

 

th

2

 

12

   

32K, Affymetriix

Not MNA not 11q-

     

23.0

  

5.3

 

4.3

   
  1. Cases are sorted on the basis of genetic category, as determined by the presence of MNA and segmental loss of 11q. Within each tumor category, cases are sorted according to age at diagnosis. Abbreviations: DOD: dead of disease; NED: no evidence of disease; SD: stable disease; WCA: whole-chromosome copy number aberration; SCA: segmental chromosomal copy number aberration; adr: adrenal; th: thoracic. Tumors marked with asterisk (*) with IDs: 52, 106, 123, 241, 240, 135, 95, 136, 111, 32, 69, 41, 107, 242, and 226 are reported also by Carén et al. [15] with the respective codes: 7, 14, 8, 2, 4, 13, 12, 37, 40, 42, 44, 39, 66, 73, and 63, as listed in [15; Table S1].